Study confirms rare CYP2C19 and CYP2D6 variants reduce drug-metabolizing activity

A new in vivo pharmacokinetic recall study involving 114 participants in the Estonian Biobank has provided the first clinical confirmation that previously uncharacterized genetic variants in the drug-metabolizing enzymes CYP2C19 and CYP2D6…

Continue Reading

News Source: medicalxpress.com